These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pulmonary hypertension update. Hesselgrave B Case Manager; 2005; 16(6):61-6; quiz 67. PubMed ID: 16326325 [No Abstract] [Full Text] [Related]
3. Epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. Botney M N Engl J Med; 1998 Jun; 338(24):1773-4. PubMed ID: 9625639 [No Abstract] [Full Text] [Related]
4. Prostacyclin analogs as the brakes for pulmonary artery smooth muscle cell proliferation: is it sufficient to treat severe pulmonary hypertension? Tuder RM; Zaiman AL Am J Respir Cell Mol Biol; 2002 Feb; 26(2):171-4. PubMed ID: 11804866 [No Abstract] [Full Text] [Related]
5. Epoprostenol therapy for primary pulmonary hypertension. Cheever KH; Kitzes B; Genthner D Crit Care Nurse; 1999 Aug; 19(4):20-7. PubMed ID: 10614244 [TBL] [Abstract][Full Text] [Related]
7. Managing patients with primary pulmonary hypertension: prostacyclin therapy. Albert NM; Hague K Am J Crit Care; 1997 Jul; 6(4):274-80. PubMed ID: 9215424 [No Abstract] [Full Text] [Related]
8. Inhaled prostacyclin: from pulmonary hypertension to splanchnic hypoperfusion. Brienza N Intensive Care Med; 1998 Nov; 24(11):1228-30. PubMed ID: 9876989 [No Abstract] [Full Text] [Related]
9. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. McLaughlin VV; Genthner DE; Panella MM; Rich S N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic evaluation of continuous intravenous epoprostenol. Chaumais MC; Jobard M; Huertas A; Vignand-Courtin C; Humbert M; Sitbon O; Rieutord A; Montani D Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1587-98. PubMed ID: 21077785 [TBL] [Abstract][Full Text] [Related]
11. [Pharmacological and clinical profile of treprostinil (TREPROST® for injection)]. Saito R; Ohmori Y Nihon Yakurigaku Zasshi; 2016 Jan; 147(1):56-62. PubMed ID: 26753860 [No Abstract] [Full Text] [Related]
12. Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Nikam VS; Schermuly RT; Dumitrascu R; Weissmann N; Kwapiszewska G; Morrell N; Klepetko W; Fink L; Seeger W; Voswinckel R Eur Respir J; 2010 Dec; 36(6):1302-14. PubMed ID: 20525716 [TBL] [Abstract][Full Text] [Related]
13. Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. Oikawa M; Kagaya Y; Otani H; Sakuma M; Demachi J; Suzuki J; Takahashi T; Nawata J; Ido T; Watanabe J; Shirato K J Am Coll Cardiol; 2005 Jun; 45(11):1849-55. PubMed ID: 15936618 [TBL] [Abstract][Full Text] [Related]
14. Effects of epoprostenol on pulmonary hypertension after pneumonectomy for trauma. Brevard S; Weintraub SL; Bronaugh H; Hunt JP; Marr AB J Trauma; 2008 Feb; 64(2):496-9. PubMed ID: 18301220 [No Abstract] [Full Text] [Related]